Guidelines for human papillomavirus DNA test requires screening in women 30 years and older

International Journal of Cancer 124, 516-520 DOI: 10.1002/ijc.24010

Citation Report

#	Article	IF	CITATIONS
1	Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China. American Journal of Epidemiology, 2009, 170, 708-716.	3.4	29
2	Integrating Human Papillomavirus Vaccination in Cervical Cancer Control Programmes. Public Health Genomics, 2009, 12, 352-361.	1.0	16
3	Evaluation of a Prototype Real-Time PCR Assay for Carcinogenic Human Papillomavirus (HPV) Detection and Simultaneous HPV Genotype 16 (HPV16) and HPV18 Genotyping. Journal of Clinical Microbiology, 2009, 47, 3344-3347.	3.9	50
4	Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. Journal of Medical Microbiology, 2009, 58, 1662-1663.	1.8	14
5	Human Papillomavirus Genotype Specificity of Hybrid Capture 2 Low-Risk Probe Cocktail. Journal of Clinical Microbiology, 2009, 47, 2611-2615.	3.9	9
6	How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer, 2009, 125, 2489-2496.	5.1	91
7	Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. Journal of Pathology, 2009, 219, 327-336.	4.5	95
9	Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. British Journal of Cancer, 2009, 101, 871-874.	6.4	82
10	Value of high-risk HPV-DNA testing in the triage of ASCUS. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 1006-1010.	2.8	10
11	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer, 2009, 45, 2714-2721.	2.8	44
12	Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importance. European Journal of Cancer, 2009, 45, 2935-2939.	2.8	77
13	How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine, 2009, 27, 5111-5119.	3.8	18
14	The evolving definition of carcinogenic human papillomavirus. Infectious Agents and Cancer, 2009, 4, 7.	2.6	33
15	Validation of high-risk HPV tests for primary cervical screening. Journal of Clinical Virology, 2009, 46, S1-S4.	3.1	62
16	Principles and analytical performance of Abbott RealTime High Risk HPV test. Journal of Clinical Virology, 2009, 45, S13-S17.	3.1	47
17	Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. Journal of Clinical Virology, 2009, 45, S19-S23.	3.1	29
18	High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. Journal of Clinical Virology, 2009, 45, S25-S28.	3.1	21
19	NucliSENS® EasyQ® HPV v1 test – Testing for oncogenic activity of human papillomaviruses. Journal of Clinical Virology, 2009, 45, S29-S37.	3.1	37

#	Article	IF	CITATIONS
20	High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products. Journal of Clinical Virology, 2009, 46, S16-S20.	3.1	44
21	High-throughput genotyping of high-risk HPV by the digene HPV Genotyping LQ Test using GP5+/6+-PCR and xMAP technology. Journal of Clinical Virology, 2009, 46, S21-S26.	3.1	31
22	HPV Screening: Available Data and Recommendations for Clinical Practice. Current Cancer Therapy Reviews, 2010, 6, 104-109.	0.3	4
23	Diagnostic efficacy of computer extracted image features in optical coherence tomography of the precancerous cervix. Medical Physics, 2011, 38, 107-113.	3.0	19
25	Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. American Journal of Obstetrics and Gynecology, 2010, 202, 581.e1-581.e5.	1.3	24
26	Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecologic Oncology, 2010, 119, 98-105.	1.4	59
27	The health and economic effects of HPV DNA screening in The Netherlands. International Journal of Cancer, 2010, 127, 2147-2158.	5.1	53
28	Methods for HPV detection in exfoliated cell and tissue specimens. Apmis, 2010, 118, 520-528.	2.0	50
29	49TH BSCC ANNUAL SCIENTIFIC MEETING KEELE 14TH SEPTEMBER 2010 - ABSTRACTS. Cytopathology, 2010, 21, i-vi.	0.7	0
30	Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. British Journal of Cancer, 2010, 103, 939-946.	6.4	16
31	Comparison of the Clinical Performance of PapilloCheck Human Papillomavirus Detection with That of the GP5+/6+-PCR-Enzyme Immunoassay in Population-Based Cervical Screening. Journal of Clinical Microbiology, 2010, 48, 797-801.	3.9	41
32	Clobal Proficiency Study of Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2010, 48, 4147-4155.	3.9	104
33	Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. Journal of Medical Screening, 2010, 17, 181-189.	2.3	20
34	Can HPV testing replace the pap smear?. Annals of the New York Academy of Sciences, 2010, 1205, 51-56.	3.8	13
35	Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology, 2010, 171, 817-825.	3.4	66
36	Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. American Journal of Epidemiology, 2010, 171, 155-163.	3.4	26
37	Special Commentary. American Journal of Clinical Pathology, 2010, 134, 193-199.	0.7	92
38	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Annals of the Rheumatic Diseases, 2010, 69, 1269-1274.	0.9	308

#	Article	IF	CITATIONS
39	Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Review of Anti-Infective Therapy, 2010, 8, 1139-1162.	4.4	108
40	Clinical Performance of the PreTect HPV-Proofer E6/E7 mRNA Assay in Comparison with That of the Hybrid Capture 2 Test for Identification of Women at Risk of Cervical Cancer. Journal of Clinical Microbiology, 2010, 48, 2779-2785.	3.9	71
43	Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. Journal of Clinical Virology, 2010, 47, 38-42.	3.1	26
44	External quality assessment for molecular detection of human papillomaviruses. Journal of Clinical Virology, 2010, 48, 251-254.	3.1	11
45	Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. Journal of Clinical Virology, 2010, 48, 246-250.	3.1	20
46	Novaprep® Vial Test is a suitable liquid-based cytology medium for high risk human papillomavirus testing by Hybrid Capture 2. Journal of Clinical Virology, 2010, 49, 286-289.	3.1	5
47	The Indicating FTA Elute Cartridge. Journal of Molecular Diagnostics, 2011, 13, 371-376.	2.8	20
48	High-Risk Human Papillomavirus Testing in Women With ASC-US Cytology. American Journal of Clinical Pathology, 2011, 135, 468-475.	0.7	304
49	Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer. Journal of Clinical Microbiology, 2011, 49, 557-564.	3.9	114
51	Human papillomavirus testing and genotyping in cervical screening. Expert Review of Anticancer Therapy, 2011, 11, 1025-1033.	2.4	9
52	Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiology, 2011, 6, 1083-1098.	2.0	121
53	Molecular Methods and Platforms for Infectious Diseases Testing. Journal of Molecular Diagnostics, 2011, 13, 583-604.	2.8	82
55	Universal human papillomavirus genotyping by the digene HPV Genotyping RH and LQ Tests. Journal of Clinical Virology, 2011, 50, 276-280.	3.1	7
56	Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population. Journal of Clinical Virology, 2011, 51, 136-138.	3.1	14
57	Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ: British Medical Journal, 2011, 342, d2757-d2757.	2.3	40
58	The molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 9-22.	28.4	2,151
59	High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix. Gynecologic Oncology, 2011, 122, 297-302.	1.4	19
60	HPV molecular assays: Defining analytical and clinical performance characteristics for cervical cytology specimens. Gynecologic Oncology, 2011, 123, 263-271.	1.4	34

#	Article	IF	CITATIONS
61	Genotyping of human papillomavirus in triaging of low-grade cervical cytology. American Journal of Obstetrics and Gynecology, 2011, 205, 145.e1-145.e6.	1.3	17
62	Management options for cervical intraepithelial neoplasia. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 641-651.	2.8	43
64	Performance of the digene LQ, RH and PS HPVs genotyping systems on clinical samples and comparison with HC2 and PCR-based Linear Array. Infectious Agents and Cancer, 2011, 6, 23.	2.6	9
65	The potential role of selfâ€sampling for highâ€risk human papillomavirus detection in cervical cancer screening. Reviews in Medical Virology, 2011, 21, 139-153.	8.3	72
66	Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. Journal of Medical Virology, 2011, 83, 272-276.	5.0	41
67	Human papillomavirus infection among women with cytological abnormalities in Switzerland investigated by an automated linear array genotyping test. Journal of Medical Virology, 2011, 83, 1370-1376.	5.0	14
68	Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 highâ€risk human papillomaviruses in cervical and anal scrapes. Journal of Medical Virology, 2011, 83, 1377-1382.	5.0	21
69	Looking ahead: A case for human papillomavirus testing of selfâ€ s ampled vaginal specimens as a cervical cancer screening strategy. International Journal of Cancer, 2011, 129, 517-527.	5.1	89
70	Validation of a Low-Cost Human Papillomavirus Genotyping Assay Based on PGMY PCR and Reverse Blotting Hybridization with Reusable Membranes. Journal of Clinical Microbiology, 2011, 49, 3474-3481.	3.9	36
71	Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening. Journal of Clinical Microbiology, 2011, 49, 1721-1729.	3.9	66
72	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology, 2011, 49, 48-53.	3.9	18
73	Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears reffered to colposcopy. Cancer Biomarkers, 2011, 7, 133-139.	1.7	11
74	Evaluation of a New DNA Test for Detection of Carcinogenic Human Papillomavirus. Journal of Clinical Microbiology, 2011, 49, 3029-3032.	3.9	31
75	Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes. Journal of Clinical Microbiology, 2011, 49, 3983-3985.	3.9	154
76	Comparison of Clinical Performance of Abbott RealTi <i>m</i> e High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting. Journal of Clinical Microbiology, 2011, 49, 1446-1451.	3.9	46
77	Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. British Journal of Cancer, 2011, 105, 694-697.	6.4	33
78	Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. British Journal of Cancer, 2011, 105, 337-339.	6.4	94
79	Human papillomavirus testing: the challenges of picking the right tools for the job. Expert Review of Obstetrics and Gynecology, 2011, 6, 643-653.	0.4	5

#	Article	IF	CITATIONS
80	Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ, The, 2012, 345, e7789-e7789.	6.0	80
81	Social Representations of Human Papillomavirus in BogotÃ _i , Colombia. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2012, 31, 77-92.	1.2	6
82	Comparison of the GenoFlow Human Papillomavirus (HPV) Test and the Linear Array Assay for HPV Screening in an Asian Population. Journal of Clinical Microbiology, 2012, 50, 1691-1697.	3.9	10
83	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 2012, 137, 516-542.	0.7	686
84	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 2012, 16, 175-204.	1.9	310
85	Clinical Validation of a Type-Specific Real-Time Quantitative Human Papillomavirus PCR against the Performance of Hybrid Capture 2 for the Purpose of Cervical Cancer Screening. Journal of Clinical Microbiology, 2012, 50, 4073-4077.	3.9	41
86	The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology. Journal of Clinical Microbiology, 2012, 50, 2289-2298.	3.9	63
87	Dry Storage and Transport of a Cervicovaginal Self-Sample by Use of the Evalyn Brush, Providing Reliable Human Papillomavirus Detection Combined with Comfort for Women. Journal of Clinical Microbiology, 2012, 50, 3937-3943.	3.9	59
88	Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical Neoplasias. Geburtshilfe Und Frauenheilkunde, 2012, 72, 507-512.	1.8	26
89	Human Papillomavirus Detection in Pregnant Women: A Prospective Matched Cohort Study. Journal of Women's Health, 2012, 21, 1295-1301.	3.3	21
90	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology, 2012, 50, 1240-1244.	3.9	24
91	Cytology and Human Papillomavirus Testing 6 to 12 Months after ASCUS or LSIL Cytology in Organized Screening To Predict High-Grade Cervical Neoplasia between Screening Rounds. Journal of Clinical Microbiology, 2012, 50, 1927-1935.	3.9	22
92	Implementing Human Papillomavirus Testing in a Public Health Hospital: Challenges and Opportunities. Acta Cytologica, 2012, 56, 160-165.	1.3	2
93	Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 3: epidemiology and public health. Future Virology, 2012, 7, 127-133.	1.8	4
94	Evaluation of a New Multiplex Real-Time Polymerase Chain Reaction Assay for the Detection of Human Papillomavirus Infections in a Referral Population. International Journal of Gynecological Cancer, 2012, 22, 1050-1056.	2.5	11
95	Colposcopic Management of Abnormal Cervical Cytology and Histology. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1188-1202.	0.7	70
96	Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer. Vaccine, 2012, 30, F88-F99.	3.8	695
97	Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncology, The, 2012, 13,	10.7	431

#	Article	IF	CITATIONS
98	Screening for Cervical Cancer and Human Papilloma Virus. Clinics in Laboratory Medicine, 2012, 32, 193-205.	1.4	3
99	Analytical Comparison of the cobas HPV Test with Hybrid Capture 2 for the Detection of High-Risk HPV Genotypes. Journal of Molecular Diagnostics, 2012, 14, 65-70.	2.8	48
100	Laboratory and clinical aspects of human papillomavirus testing. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 117-136.	6.1	37
102	Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Vaccine, 2012, 30, 5215-5221.	3.8	36
103	Cervical screening: primary human papillomavirus testing. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 650-652.	2.3	1
104	Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting. Journal of Clinical Virology, 2012, 53, 121-124.	3.1	16
105	Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: High concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. Journal of Clinical Virology, 2012, 54, 147-151.	3.1	40
107	Immunomarkers in Gynecologic Cytology: The Search for the Ideal †Biomolecular Papanicolaou Test'. Acta Cytologica, 2012, 56, 109-121.	1.3	46
108	Detection of Human Papillomavirus DNA and RNA. Monographs in Virology, 2012, , 109-119.	0.6	0
109	High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clinical Chemistry and Laboratory Medicine, 2012, 50, 655-61.	2.3	59
110	Comparison of INNO-LiPA Genotyping Extra and Hybrid Capture 2 assays for detection of carcinogenic human papillomavirus genotypes. Journal of Clinical Virology, 2012, 55, 256-261.	3.1	20
111	Biomarkers for cervical cancer screening: the role of p16 ^{INK4a} to highlight transforming HPV infections. Expert Review of Proteomics, 2012, 9, 149-163.	3.0	61
112	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. Vaccine, 2012, 30, F100-F106.	3.8	91
113	Molecular Diagnosis of Human Papillomavirus. , 2012, , .		1
114	Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus. Annals of Laboratory Medicine, 2012, 32, 201-205.	2.5	19
115	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 147-172.	329.8	1,022
116	Selfâ€sampling of vaginal fluid and highâ€risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 245-248.	2.3	22
117	Alternative approaches to cervical cancer screening for developing countries. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 197-208.	2.8	63

#	Article	IF	CITATIONS
118	Molecular methods for pathogen and microbial community detection and characterization: Current and potential application in diagnostic microbiology. Infection, Genetics and Evolution, 2012, 12, 505-521.	2.3	123
119	Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecologic Oncology, 2012, 125, 343-345.	1.4	49
120	Experience with highâ€risk human papillomavirus testing on vaginal brushâ€based selfâ€samples of nonâ€attendees of the cervical screening program. International Journal of Cancer, 2012, 130, 1128-1135.	5.1	101
121	Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. International Journal of Cancer, 2013, 132, 916-923.	5.1	37
122	HPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease. Current Obstetrics and Gynecology Reports, 2013, 2, 76-85.	0.8	15
124	Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. Journal of Clinical Virology, 2013, 58, 161-167.	3.1	11
125	Understanding HPV tests and their appropriate applications. Cytopathology, 2013, 24, 289-308.	0.7	36
126	Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia. Vaccine, 2013, 31, H71-H79.	3.8	18
127	Prevalence of Human Papillomavirus Infection in Unselected SurePath Samples Using the APTIMA HPV mRNA Assay. Journal of Molecular Diagnostics, 2013, 15, 670-677.	2.8	21
128	Viral Load of High-Risk Human Papillomaviruses as Reliable Clinical Predictor for the Presence of Cervical Lesions. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 406-414.	2.5	43
129	Trials and Projects on Cervical Cancer and Human Papillomavirus Prevention in Sub-Saharan Africa. Vaccine, 2013, 31, F53-F59.	3.8	33
130	Nonâ€inferiority and superiority tests for partially matched data when a constraint is placed on the number of new tests. Statistics in Medicine, 2013, 32, 2515-2528.	1.6	2
131	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2013, 14, 168-176.	10.7	139
133	Clinical evaluation of high-risk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge. Journal of Clinical Virology, 2013, 57, 125-129.	3.1	27
134	Human Papillomavirus Testing in Cervical Cancer Screening. Obstetrics and Gynecology Clinics of North America, 2013, 40, 377-390.	1.9	13
135	HPV Direct Flow CHIP: A new human papillomavirus genotyping method based on direct PCR from crude-cell extracts. Journal of Virological Methods, 2013, 193, 9-17.	2.1	28
136	Detection and genotyping of human papillomavirus by five assays according to cytologic results. Journal of Virological Methods, 2013, 187, 79-84.	2.1	10
137	Use of the Nucli <scp>SENS</scp> Easy <scp>Q</scp> <scp>HPV</scp> assay in the management of cervical intraepithelial neoplasia. Journal of Medical Virology, 2013, 85, 1235-1241.	5.0	16

#	Article	IF	CITATIONS
138	Highâ€risk HPV testing on selfâ€sampled <i>versus</i> clinicianâ€collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. International Journal of Cancer, 2013, 132, 2223-2236.	5.1	210
139	The Problem of False-Positive Human Papillomavirus DNA Tests in Cervical Screening. Current Pharmaceutical Design, 2013, 19, 1439-1449.	1.9	2
140	Hybrid Capture 2 Test Results After an Initial Equivocal RLU/CO Value Are Dependent on Age. American Journal of Clinical Pathology, 2013, 139, 605-610.	0.7	2
141	Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer. BioMed Research International, 2013, 2013, 1-10.	1.9	96
142	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. Journal of Clinical Microbiology, 2013, 51, 2901-2907.	3.9	26
143	Development and Characterization of the cobas Human Papillomavirus Test. Journal of Clinical Microbiology, 2013, 51, 1478-1484.	3.9	70
144	Human Papillomavirus Detection. Advances in Anatomic Pathology, 2013, 20, 158-167.	4.3	29
145	The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. Journal of Clinical Microbiology, 2013, 51, 3653-3657.	3.9	52
146	Clinical Validation of the Abbott RealTi <i>m</i> e High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical Screening. Journal of Clinical Microbiology, 2013, 51, 2409-2410.	3.9	40
147	How much could primary human papillomavirus testing reduce cervical cancer incidence and morbidity?. Journal of Medical Screening, 2013, 20, 99-103.	2.3	17
148	Performance of proex c and pretect hpvâ€proofer e6/e7 mrna tests in comparison with the hybrid capture 2 hpv dna test for triaging ascus and Isil cytology. Diagnostic Cytopathology, 2013, 41, 767-775.	1.0	24
149	Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and metaâ€analysis. Cancer Medicine, 2013, 2, 367-390.	2.8	17
150	Comparing the performance of six human papillomavirus tests in a screening population. British Journal of Cancer, 2013, 108, 908-913.	6.4	173
151	The Present and Future of Cervical Cancer Screening Programmes in Europe. Current Pharmaceutical Design, 2013, 19, 1490-1497.	1.9	12
152	Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions. Current Pharmaceutical Design, 2013, 19, 1358-1370.	1.9	9
153	Practice Bulletin No. 140. Obstetrics and Gynecology, 2013, 122, 1338-1366.	2.4	82
154	Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. Oncology Letters, 2013, 6, 215-219.	1.8	19
155	HPV Testing by cobas HPV Test in a Population from Catalonia. PLoS ONE, 2013, 8, e58153.	2.5	27

#	Article	IF	CITATIONS
156	Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay. PLoS ONE, 2013, 8, e59765.	2.5	44
157	HPV Diagnosis in Vaccination Era. , 2013, , .		0
158	Pre-analytical and post-analytical evaluation in the era of molecular diagnosis of sexually transmitted diseases: cellularity control and internal control. Microbiologia Medica, 2014, 29, .	0.1	0
159	A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology. Clinical Interventions in Aging, 2014, 9, 683.	2.9	9
160	Comparing the Cervista HPV HR Test and Hybrid Capture 2 Assay in a Dutch Screening Population: Improved Specificity of the Cervista HPV HR Test by Changing the Cut-Off. PLoS ONE, 2014, 9, e101930.	2.5	11
161	Clinical application of DNA ploidy to cervical cancer screening: A review. World Journal of Clinical Oncology, 2014, 5, 931.	2.3	34
162	Clinical Validation of the HPV-Risk Assay, a Novel Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus DNA by Targeting the E7 Region. Journal of Clinical Microbiology, 2014, 52, 890-896.	3.9	52
163	Laboratory Diagnosis of Human Papillomavirus Infection. Current Problems in Dermatology, 2014, 45, 166-174.	0.7	8
164	Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology. Gynecologic Oncology, 2014, 135, 474-480.	1.4	27
165	Global Improvement in Genotyping of Human Papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. Journal of Clinical Microbiology, 2014, 52, 449-459.	3.9	72
166	The current position and the future perspectives of cervical cancer screening. Expert Review of Anticancer Therapy, 2014, 14, 75-92.	2.4	25
167	Applicability of self-obtained urine and vaginal samples for HPV-16, -18, -31 and -45 cervical cancer screening in pregnancy: a pilot cross-sectional study. Future Virology, 2014, 9, 385-395.	1.8	1
168	Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control. Journal of Clinical Microbiology, 2014, 52, 3996-4002.	3.9	40
169	Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Annals of Oncology, 2014, 25, 927-935.	1.2	74
170	GuÃa de cribado del cáncer de cuello de útero en España, 2014. Progresos En Obstetricia Y Ginecologia, 2014, 57, 1-53.	0.0	18
171	Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64Âyears of age in the Gurage zone, rural Ethiopia. Infectious Agents and Cancer, 2014, 9, 33.	2.6	31
172	cobas [®] 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Review of Molecular Diagnostics, 2014, 14, 5-16.	3.1	21
173	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. Journal of Clinical Microbiology, 2014, 52, 2892-2897.	3.9	29

#	Article	IF	CITATIONS
174	From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice. Cancers, 2014, 6, 2072-2099.	3.7	26
175	Tissue Genotyping of 37 In Situ and Invasive Cervical Cancer With a Concomitant Negative HC2 HPV DNA Test. Journal of Lower Genital Tract Disease, 2014, 18, 87-91.	1.9	15
176	Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV Assay for Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2014, 52, 607-612.	3.9	52
178	Comparison of the performance of the NucliSENS EasyQ HPV E6/E7 mRNA assay and HPV DNA chip for testing squamous cell lesions of the uterine cervix. Diagnostic Microbiology and Infectious Disease, 2014, 79, 422-427.	1.8	13
179	Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. Preventive Medicine, 2014, 64, 108-113.	3.4	70
181	Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. Journal of Clinical Virology, 2014, 59, 246-249.	3.1	54
182	Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening. Journal of Virological Methods, 2014, 205, 57-60.	2.1	6
183	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncology, The, 2014, 15, 172-183.	10.7	508
184	Human papillomavirus detection and genotyping, by HC2, full-spectrum HPV and molecular beacon real-time HPV assay in an Irish colposcopy clinic. Journal of Virological Methods, 2014, 201, 93-100.	2.1	4
185	Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru. Brazilian Journal of Infectious Diseases, 2014, 18, 469-472.	0.6	19
186	p16 ^{INK4A} immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China. International Journal of Cancer, 2014, 134, 1715-1724.	5.1	57
188	Clinical Validation of the Cervista HPV HR Test According to the International Guidelines for Human Papillomavirus Test Requirements for Cervical Cancer Screening. Journal of Clinical Microbiology, 2014, 52, 4391-4393.	3.9	20
189	Reply to P.E. Castle. Journal of Clinical Oncology, 2014, 32, 361-362.	1.6	3
190	An evaluation of the Qiagen HPV sign for the detection and genotyping of cervical lesions and oropharyngeal squamous cell carcinomas. Journal of Virological Methods, 2014, 207, 128-132.	2.1	2
191	Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with ThinPrep® Pap test samples. Experimental and Molecular Pathology, 2014, 97, 279-284.	2.1	20
192	Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. BMC Cancer, 2014, 14, 207.	2.6	24
193	Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China. Journal of Clinical Microbiology, 2014, 52, 1954-1961.	3.9	14
194	Human Papillomavirus (HPV) Testing for Secondary Prevention of Cervical Cancer. Current Obstetrics and Gynecology Reports, 2015, 4, 201-212.	0.8	4

#	Article	IF	CITATIONS
	Comparison of two surgical methods for the treatment of CIN: classical LLETZ (large-loop excision of) Tj ETQq0 0	0 rgBT /O [,]	verlock 10 Tf
195	protocol for a randomized controlled trial. Trials, 2015, 16, 225.	1.6	6
196	Comparing the Relative Efficacy of Narrative vs Nonnarrative Health Messages in Reducing Health Disparities Using a Randomized Trial. American Journal of Public Health, 2015, 105, 2117-2123.	2.7	97
197	Comparative analysis of cervical cytology and human papillomavirus genotyping by three different methods in a routine diagnostic setting. European Journal of Cancer Prevention, 2015, 24, 447-453.	1.3	3
198	Visual Inspection of Cervix With Acetic Acid as a Screening Modality for Cervical Cancer. Journal of Lower Genital Tract Disease, 2015, 19, 340-344.	1.9	8
199	Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus. Journal of Medical Virology, 2015, 87, 1587-1593.	5.0	5
201	Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World Journal of Clinical Oncology, 2015, 6, 281.	2.3	185
202	Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology. PLoS ONE, 2015, 10, e0119755.	2.5	88
203	Development of a Multiplex PCR Test with Automated Genotyping Targeting E7 for Detection of Six High-Risk Human Papillomaviruses. PLoS ONE, 2015, 10, e0130226.	2.5	6
204	Comparison of Analytical and Clinical Performances of the Digene HC2 HPV DNA Assay and the INNO-LiPA HPV Genotyping Assay for Detecting High-Risk HPV Infection and Cervical Neoplasia Among HIV-Positive African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 162-168.	2.1	19
205	Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies. Clinical Science, 2015, 128, 153-180.	4.3	12
207	High-risk HPV detection and genotyping by APTIMA HPV using cervical samples. Journal of Virological Methods, 2015, 221, 95-99.	2.1	4
208	Reliability of the Xpert HPV Assay to Detect High-Risk Human Papillomavirus DNA in a Colposcopy Referral Population. American Journal of Clinical Pathology, 2015, 143, 126-133.	0.7	44
209	Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. Clinical Microbiology and Infection, 2015, 21, 806-807.	6.0	7
210	Offering Self-Sampling to Non-Attendees of Organized Primary HPV Screening: When Do Harms Outweigh the Benefits?. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 773-782.	2.5	42
211	The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology. Journal of Clinical Virology, 2015, 69, 52-55.	3.1	10
212	Comparison of Hybribio GenoArray and Roche Human Papillomavirus (HPV) Linear Array for HPV Genotyping in Anal Swab Samples. Journal of Clinical Microbiology, 2015, 53, 550-556.	3.9	14
213	Publisher's note. Journal of Virological Methods, 2015, 213, i.	2.1	1
214	Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. Journal of Clinical Microbiology, 2015, 53, 2509-2516.	3.9	73

#	Article	IF	CITATIONS
215	<scp>HPV</scp> â€negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 119-127.	2.3	168
216	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	2.5	44
217	Cervista HPV HR Test for Cervical Cancer Screening: A Comparative Study in the Catalonian Population. Archives of Pathology and Laboratory Medicine, 2015, 139, 241-244.	2.5	9
218	Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clinical Microbiology and Infection, 2015, 21, 817-826.	6.0	234
219	The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra. Journal of Virological Methods, 2015, 215-216, 22-29.	2.1	32
220	The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. Journal of Clinical Microbiology, 2015, 53, 3553-3559.	3.9	9
221	Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework. Journal of Clinical Microbiology, 2015, 53, 3272-3279.	3.9	50
222	HPV Genotyping in the Prevention of Cervical Cancer—How and When Can It Be a Useful Marker?. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1302-1303.	2.5	1
223	Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions. Journal of Clinical Microbiology, 2015, 53, 2109-2114.	3.9	21
224	Comparison of the performance of <scp>HPV</scp> tests in women with abnormal cytology: results of a study within the <scp>NHS</scp> cervical screening programme. Cytopathology, 2015, 26, 373-380.	0.7	16
225	Management of women with low grade cytology: how reassuring is a normal colposcopy examination?. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 380-386.	2.3	17
226	Cervical cancer screening based on human papilloma virus-DNA testing: a scientific heritage to microbiologists or to pathologists? An on-going dilemma. Microbiologia Medica, 2016, 31, .	0.1	0
227	Practice Bulletin No. 157. Obstetrics and Gynecology, 2016, 127, e1-e20.	2.4	99
228	Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. Journal of Medical Virology, 2016, 88, 1271-1278.	5.0	14
229	Molecular diagnosis of infectious diseases using cytological specimens. Diagnostic Cytopathology, 2016, 44, 156-164.	1.0	15
230	Prise en charge colposcopique des résultats cytologiques et histologiques anormaux en ce qui concerne le col utA©rin. Journal of Obstetrics and Cynaecology Canada, 2016, 38, S171-S188.	0.7	0
231	ACOG. Obstetrics and Gynecology, 2016, 128, e111-e130.	2.4	175
233	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway—PaVDaG study). BMJ Open, 2016, 6, e010660.	1.9	64

#	Article	IF	CITATIONS
234	Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework. Journal of Clinical Virology, 2016, 81, 6-11.	3.1	25
235	Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea. Archives of Pathology and Laboratory Medicine, 2016, 140, 276-280.	2.5	21
236	Distribution of human papillomaviruses and bacterial vaginosis in HIV positive women with abnormal cytology in Mombasa, Kenya. Infectious Agents and Cancer, 2016, 11, 17.	2.6	20
237	Improving Laboratory Efficiency by Automation of Preanalytic Processing of ThinPrep Specimens for Real-Time PCR High-Risk HPV Testing. Journal of the Association for Laboratory Automation, 2016, 21, 432-438.	2.8	3
238	Electrochemical chip-based genomagnetic assay for detection of high-risk human papillomavirus DNA. Biosensors and Bioelectronics, 2016, 83, 300-305.	10.1	40
239	EUROarray human papillomavirus (HPV) assay is highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1033-1036.	2.9	6
240	p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Modern Pathology, 2016, 29, 870-878.	5.5	43
241	Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. British Journal of Cancer, 2016, 115, 525-532.	6.4	14
242	Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests). Journal of Clinical Microbiology, 2016, 54, 2337-2342.	3.9	48
243	FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. British Journal of Cancer, 2016, 115, 579-587.	6.4	55
244	Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays. Journal of Clinical Microbiology, 2016, 54, 2669-2675.	3.9	28
245	Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infectious Diseases, 2016, 16, 698.	2.9	10
246	HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows. BMC Cancer, 2016, 16, 922.	2.6	27
247	Patterns of Care and Outcome of Elderly Women Diagnosed With Cervical Cancer in the Developing World. International Journal of Gynecological Cancer, 2016, 26, 1246-1251.	2.5	17
248	Comparing the performance of <i>FAM19A4</i> methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in highâ€risk HPVâ€positive women of a gynecologic outpatient population (COMETH study). International Journal of Cancer, 2016, 138, 992-1002.	5.1	60
249	The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening. Journal of Clinical Microbiology, 2016, 54, 2267-2272.	3.9	30
250	Clinical validation of Anyplexâ,,¢ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening. Journal of Clinical Virology, 2016, 76, 36-39.	3.1	47
251	Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. Journal of Clinical Virology, 2016, 76, S3-S13.	3.1	105

#	Article	IF	CITATIONS
252	HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance. Journal of Clinical Virology, 2016, 76, S22-S28.	3.1	14
253	Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. Journal of Clinical Virology, 2016, 76, S29-S39.	3.1	18
255	La detección de virus del papiloma humano es una herramienta más protectora frente al cáncer cervical que la citologÃa. Revista Espanola De Patologia, 2016, 49, 135-136.	0.2	0
256	Laboratory audit as part of the quality assessment of a primary HPV-screening program. Journal of Clinical Virology, 2016, 75, 33-36.	3.1	17
257	Clinical validation of a novel real-time human papillomavirus assay for simultaneous detection of 14 high-risk HPV type and genotyping HPV type 16 and 18 in China. Archives of Virology, 2016, 161, 449-454.	2.1	10
258	Implications of semi-quantitative HPV viral load estimation by Hybrid capture 2 in colposcopy practice. Journal of Medical Screening, 2016, 23, 104-110.	2.3	12
259	HPV testing in the context of post-treatment follow up (test of cure). Journal of Clinical Virology, 2016, 76, S56-S61.	3.1	43
260	A review of the clinical performance of the Aptima HPV assay. Journal of Clinical Virology, 2016, 76, S40-S48.	3.1	73
261	VALGENT: A protocol for clinical validation of human papillomavirus assays. Journal of Clinical Virology, 2016, 76, S14-S21.	3.1	123
262	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. Expert Review of Molecular Diagnostics, 2017, 17, 379-391.	3.1	55
263	Diagnóstico microbiológico de la infección por virus del papiloma humano. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 593-602.	0.5	6
264	Molecular approaches for HPV genotyping and HPV-DNA physical status. Expert Reviews in Molecular Medicine, 2017, 19, e1.	3.9	45
265	The clinical implementation of primary <scp>HPV</scp> screening. International Journal of Gynecology and Obstetrics, 2017, 136, 266-271.	2.3	5
266	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	3.4	87
267	Anal cancer screening: Techniques and guidelines. Seminars in Colon and Rectal Surgery, 2017, 28, 69-74.	0.3	7
268	High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: Results of the VERA study. Preventive Medicine, 2017, 101, 96-101.	3.4	71
269	Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening. Journal of Lower Genital Tract Disease, 2017, 21, 12-16.	1.9	26
270	HPV-based cervical cancer screening- facts, fiction, and misperceptions. Preventive Medicine, 2017, 98, 33-35.	3.4	43

ARTICLE IF CITATIONS External quality assessment for human papillomavirus 16/18 DNA detection and genotyping in 271 2.3 8 Shanghai, China. Clinical Chemistry and Laboratory Medicine, 2017, 55, 195-202. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ 1.0 lesions in young women. Diagnostic Cytopathology, 2017, 45, 1065-1072. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel. Journal of 273 3.9 30 Clinical Microbiology, 2017, 55, 3544-3551. Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath. American Journal of Clinical Pathology, 2017, 148, 450-457. 274 Defining Optimal Triage Strategies for hrHPV Screen–Positive Women—An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry. Cancer Epidemiology Biomarkers and 275 2.5 36 Prevention, 2017, 26, 1629-1635. Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. Cytopathology, 2017, 28, 419-428. The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias. Geburtshilfe Und 277 1.8 10 Frauenheilkunde, 2017, 77, 887-893. Comparison of the analytical and clinical performance of five tests for the detection of human 278 2.1 9 papillomavirus genital infection. Journal of Virological Methods, 2017, 248, 238-243. Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders. Journal of 279 3.9 15 Clinical Microbiology, 2017, 55, 2913-2923. Evaluation of the Xpert® HPV assay in the detection of Human Papillomavirus in formalin-fixed 1.5 paraffin-embedded oropharyngeal carcinomas. Oral Oncology, 2017, 72, 117-122. HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples. Papillomavirus Research (Amsterdam, Netherlands), 281 4.515 2017, 4, 79-84. Microbiological diagnosis of human papilloma virus infection. Enfermedades Infecciosas Y 0.3 Microbiologia Clinica (English Ed), 2017, 35, 593-602. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. 283 0.5 121 Journal of Global Oncology, 2017, 3, 635-657. Performance of <scp>mRNA</scp>â€and <scp>DNA</scp>â€based highâ€risk human papillomavirus assays in detection of highâ€grade cervical lesions. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 61-68. 284 2.8 Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical 285 2.9 15 abnormalities. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 545-551. Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection. Journal of Clinical Laboratory Analysis, 2017, 31, e22025. Epidemiological study of highâ€ʻrisk human papillomavirus infection in subjects with abnormal 287 cytological findings in cervical cancer screening. Experimental and Therapeutic Medicine, 2018, 15, 1.8 13 412-4**1**8. HPV diagnostic testing under the new Australian National Cervical Screening Program, including 289 self-collection. Journal of Virus Eradication, 2017, 3, 6-7.

#	Article	IF	CITATIONS
291	Human papillomavirus detection using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female population. Virology Journal, 2017, 14, 241.	3.4	5
292	The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women. Clinical Microbiology and Infection, 2018, 24, 1322-1327.	6.0	15
293	Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. Journal of Clinical Virology, 2018, 101, 74-85.	3.1	34
294	Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. Journal of Clinical Virology, 2018, 98, 37-42.	3.1	35
295	Not all HPV nucleic acid tests are equal: only those calibrated to detect high grade lesions matter for cervical screening. Clinical Microbiology and Infection, 2018, 24, 436-437.	6.0	2
296	Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human Papillomavirus. Journal of Clinical Microbiology, 2018, 56, .	3.9	5
297	Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. Journal of Clinical Virology, 2018, 99-100, 22-30.	3.1	32
298	Comparison of the digene hybrid capture 2 and Roche cobas 4800 HPV tests for detection of CIN2+ in a referral population in Japan. Journal of Medical Virology, 2018, 90, 972-980.	5.0	7
299	Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening. Virology Journal, 2018, 15, 48.	3.4	10
300	Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods. Infectious Diseases, 2018, 50, 554-559.	2.8	4
301	Cervical screening in HPV-vaccinated populations. Climacteric, 2018, 21, 227-234.	2.4	8
302	Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review. Clinical Microbiology and Infection, 2018, 24, 29-36.	6.0	33
303	Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation. European Journal of Cancer Prevention, 2018, 27, 46-53.	1.3	5
304	Quality Control of HPV Test. Journal of Women's Health Care, 2018, 07, .	0.2	0
305	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
306	Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1232-1244.	1.8	2
307	Population-based e-records to evaluate HPV triage of screen-detected atypical squamous cervical lesions in Catalonia, Spain, 2010–15. PLoS ONE, 2018, 13, e0207812.	2.5	2
309	Genital human papillomavirus infections. Frontiers in Bioscience - Landmark, 2018, 23, 1587-1611.	3.0	8

#	Article	IF	CITATIONS
310	Clinical validation of the Cervista [®] high-risk human papillomavirus test in Chinese women from Fujian province: a cross-sectional study. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2243-2253.	2.0	2
311	Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses, 2018, 10, 729.	3.3	161
313	Cervical dysplasia in elderly women performing repeated self-sampling for HPV testing. PLoS ONE, 2018, 13, e0207714.	2.5	15
314	Cervical cancer screening using the Cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Management and Research, 2018, Volume 10, 3227-3235.	1.9	7
315	The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. Journal of Clinical Virology, 2018, 108, 64-71.	3.1	37
316	HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population—Cobas and Aptima HPV tests. Journal of Clinical Virology, 2018, 109, 13-18.	3.1	4
317	Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework. International Journal of Molecular Sciences, 2018, 19, 2704.	4.1	23
318	Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. Journal of Clinical Virology, 2018, 108, 32-37.	3.1	20
319	Validation of EUROArray HPV test using the VALGENT framework. Journal of Clinical Virology, 2018, 108, 38-42.	3.1	18
320	Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework. Journal of Clinical Microbiology, 2018, 56, .	3.9	20
321	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. Journal of Clinical Virology, 2018, 107, 52-56.	3.1	72
322	A Head-to-Head Analytical Comparison of Cobas 4800 HPV, PapilloCheck HPV Screening, and LMNX Genotyping Kit HPV GP for Detection of Human Papillomavirus DNA in Cervical and Cervicovaginal Swabs. Journal of Molecular Diagnostics, 2018, 20, 849-858.	2.8	10
323	Impact of operational factors on HPV positivity rates in an HPVâ€based screening study in Colombia. International Journal of Gynecology and Obstetrics, 2018, 143, 44-51.	2.3	1
324	Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 192-200.	4.5	24
325	The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality. Journal of Pathology: Clinical Research, 2018, 4, 207-212.	3.0	7
326	Proposal for cervical cancer screening in the era of HPV vaccination. Obstetrics and Gynecology Science, 2018, 61, 298.	1.6	13
327	High-Risk Types of Human Papilloma Virus DNA Testing in Women with False Negative Cytology. Acta Cytologica, 2018, 62, 411-417.	1.3	0
328	Comparison of Siriraj liquidâ€based solution and standard transport media for the detection of highâ€risk human papillomavirus in cervical specimens. Journal of Medical Virology, 2018, 90, 1793-1799.	5.0	Ο

#	Article	IF	CITATIONS
329	Update on primary HPV screening for cervical cancer prevention. Current Problems in Cancer, 2018, 42, 507-520.	2.0	22
330	Frequency and coinfection between genotypes of human papillomavirus in a population of asymptomatic women in northern Peru. BMC Research Notes, 2018, 11, 530.	1.4	3
331	Comparison between professional sampling and selfâ€sampling for <scp>HPV</scp> â€based cervical cancer screening among postmenopausal women. International Journal of Gynecology and Obstetrics, 2018, 142, 359-364.	2.3	8
332	HPVâ€mRNA and HPVâ€DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. International Journal of Cancer, 2019, 144, 1073-1081.	5.1	22
335	A review of the FDA-approved molecular testing platforms for human papillomavirus. Journal of the American Society of Cytopathology, 2019, 8, 284-292.	0.5	54
336	CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology. Virology Journal, 2019, 16, 92.	3.4	6
337	Fiveâ€year risk of CIN 3 after shortâ€term HPV ―DNA negativity in cytologyâ€negative women: a populationâ€based cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 1365-1371.	2.3	5
338	Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention. BMC Infectious Diseases, 2019, 19, 842.	2.9	10
339	Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel. Journal of Clinical Virology, 2019, 121, 104201.	3.1	9
340	Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings. Journal of Clinical Microbiology, 2019, 58, .	3.9	13
342	Predictors of cervical cancer screening practice among HIV positive women attending adult anti-retroviral treatment clinics in Bishoftu town, Ethiopia: the application of a health belief model. BMC Cancer, 2019, 19, 989.	2.6	31
343	Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening. Virology Journal, 2019, 16, 107.	3.4	18
344	Analytical Evaluation of the Human Papillomavirus HPV DNA Array E1-Based Genotyping Assay. Intervirology, 2019, 62, 124-133.	2.8	3
345	Profile of MeltPro® HPV test for human papillomavirus genotyping and cervical precancer screening. Expert Review of Molecular Diagnostics, 2019, 19, 857-862.	3.1	3
346	Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay. Journal of Clinical Virology, 2019, 120, 57-62.	3.1	12
348	Ensuring quality in cervical screening programmes based on molecular human papillomavirus testing. Cytopathology, 2019, 30, 273-280.	0.7	6
349	Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population. PLoS ONE, 2019, 14, e0210997.	2.5	18
350	Biomarkers for theÂEarly Detection of Cervical Cancer. , 2019, , 117-129.		0

#	Article	IF	CITATIONS
351	Improving laboratory workflow through automated preâ€processing of SurePath specimens for human papillomavirus testing with the Abbott RealTi m e assay. Cytopathology, 2019, 30, 532-537.	0.7	0
352	HPV-based screening for cervical cancer among women 55-59 years of age. PLoS ONE, 2019, 14, e0217108.	2.5	16
353	Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies. Expert Review of Molecular Diagnostics, 2019, 19, 543-551.	3.1	11
354	Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens. Acta Cytologica, 2019, 63, 379-384.	1.3	14
355	A randomized trial comparing limited-excision conisation to Large Loop Excision of the Transformation Zone (LLETZ) in cervical dysplasia patients. Journal of Gynecologic Oncology, 2019, 30, e42.	2.2	10
356	Human Papillomavirus Research: Where Should We Place Our Bets?. Acta Cytologica, 2019, 63, 85-96.	1.3	5
357	A direct comparison of four highâ€risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in lowâ€resource settings. Journal of Medical Virology, 2019, 91, 1342-1350.	5.0	9
358	HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system. BMC Women's Health, 2019, 19, 47.	2.0	11
359	Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland. Gynecologic Oncology, 2019, 153, 92-99.	1.4	16
360	Comparing two visualization protocols for tomosynthesis in screening: specificity and sensitivity of slabs versus planes plus slabs. European Radiology, 2019, 29, 3802-3811.	4.5	14
361	Intra―and interâ€laboratory agreement of the FAM19A4/mir124â€2 methylation test: Results from an international study. Journal of Clinical Laboratory Analysis, 2019, 33, e22854.	2.1	26
362	Evaluating the PGMY-Centre Hospitalier Universitaire Vaudois Assay as a Cost-effective Tool for Human Papillomavirus Genotyping in HIV-infected Women. Indian Journal of Medical Microbiology, 2019, 37, 542-548.	0.8	1
363	Comparison of CerviHPV and Hybrid Capture 2 HPV tests for detection of highâ€risk HPV infection in cervical swab specimens. Diagnostic Cytopathology, 2019, 47, 439-444.	1.0	6
364	Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening. Journal of Clinical Microbiology, 2019, 57, .	3.9	20
365	Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncology, The, 2019, 20, 229-238.	10.7	129
366	HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Preventive Medicine, 2019, 119, 108-117.	3.4	67
367	Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. Journal of Clinical Microbiology, 2019, 57, .	3.9	26
368	Comparison Study of BD Onclarity HPV WithdigeneHC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan. American Journal of Clinical Pathology, 2019, 151, 263-269.	0.7	11

	CITATION	n Report	
#	Article	IF	Citations
369	Analytical performance of a lowâ€cost multiplex polymerase chain reaction human papillomavirus genotyping assay for use in Subâ€Saharan Africa. Journal of Medical Virology, 2019, 91, 308-316.	5.0	6
370	Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clinical Microbiology and Infection, 2020, 26, 579-583.	6.0	165
371	Clinical performance of the HPV DNA Array genotyping assay in detection of CIN2+ lesions with BS GP5+/6+ÂMPG Luminex tested cervical samples. Journal of Medical Virology, 2020, 92, 113-118.	5.0	2
372	Developing and Standardizing Human Papillomavirus Tests. , 2020, , 111-130.		3
373	Triage of Women With ASCUS and LSIL Abnormal Cytology: The ALTS Experience and Beyond. , 2020, , 235-243.		0
374	Primary Screening by Human Papillomavirus Testing: Development, Implementation, and Perspectives. , 2020, , 245-268.		Ο
375	A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. European Journal of Cancer Prevention, 2020, 29, 157-164.	1.3	9
376	Comparison of the Hybrid Capture II Method with a PCR-Based Screening Method Using a Carboxyfluorescein-Labeled Primer for Detecting Human Papillomavirus in Cervicovaginal Liquid-Based Cytology. Journal of Molecular Pathology, 2020, 1, 9-18.	1.2	3
377	The clinical performance of human papillomavirus genotyping using PANArray HPV chip: Comparison to ThinPrep cytology alone and co-testing. Pathology Research and Practice, 2020, 216, 153121.	2.3	0
379	Methodologies of Primary HPV Testing Currently Applied for Cervical Cancer Screening. Life, 2020, 10, 290.	2.4	15
380	Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women. Cancer Medicine, 2020, 9, 6813-6824.	2.8	21
381	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers. Cancer Prevention Research, 2020, 13, 829-840.	1.5	6
382	Actualización en el diagnóstico de las infecciones de transmisión sexual. Actas Dermo-sifiliográficas, 2020, 111, 711-724.	0.4	6
383	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. Ca-A Cancer Journal for Clinicians, 2020, 70, 321-346.	329.8	481
384	Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes. Acta Oncológica, 2020, 59, 1308-1315.	1.8	5
385	Update on the Diagnosis of Sexually Transmitted Infections. Actas Dermo-sifiliogrÃ _i ficas, 2020, 111, 711-724.	0.4	5
386	Self-Collection for Cervical Screening Programs: From Research to Reality. Cancers, 2020, 12, 1053.	3.7	46
387	The use of micro RNA in the early detection of cervical intraepithelial neoplasia. Carcinogenesis, 2020, 41, 1781-1789.	2.8	4

#	Article	IF	CITATIONS
388	Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. BMJ Open, 2020, 10, e031303.	1.9	16
389	Cervical cancer screening – The challenges of complete pathways of care in low-income countries: Focus on Malawi. Women's Health, 2020, 16, 174550652091480.	1.5	39
390	Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening. BMC Cancer, 2020, 20, 396.	2.6	9
391	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	6.4	74
392	Performance analysis of highâ€ŧhroughput HPV testing on three automated workflows. Apmis, 2020, 128, 497-505.	2.0	4
393	Primary HPV screening for cervical cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 98-108.	2.8	91
394	Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. The Lancet Global Health, 2020, 8, e296-e304.	6.3	41
395	Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. Journal of Clinical Microbiology, 2020, 58, .	3.9	24
396	Commercially available molecular tests for human papillomaviruses: a global overview. Clinical Microbiology and Infection, 2020, 26, 1144-1150.	6.0	84
397	Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework. Journal of Clinical Microbiology, 2020, 58, .	3.9	7
398	Colposcopic endocervical brushing cytology appears to be more sensitive than histologic endocervical curettage for detecting endocervical adenocarcinoma. Journal of the American Society of Cytopathology, 2021, 10, 135-140.	0.5	3
399	Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 403-409.	2.8	9
400	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 268-277.	2.5	24
401	Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancerÂscreening program. American Journal of Obstetrics and Gynecology, 2021, 224, 200.e1-200.e9.	1.3	18
402	Head and neck cancer: Current challenges and future perspectives. Advances in Cancer Research, 2021, 152, 67-102.	5.0	41
403	Validation of the cobas 6800 human papillomavirus test in primary cervical screening. PLoS ONE, 2021, 16, e0247291.	2.5	3
404	Performance Indicators of Cervical Cancer Screening Program Based on The Guidelines of Iran Ministry of Health and Medical Education. International Journal of Cancer Management, 2021, 14, .	0.4	2
405	Human Papillomavirus Distribution in Women with Abnormal Pap Smear and/or Cervical Intraepithelial Neoplasia in Vaccination Era. A Single-Center Study in the North Italian Population. Microorganisms. 2021. 9. 729.	3.6	4

#	Article	IF	CITATIONS
406	Evaluation of the Onclarity HPV assay on the high-throughput COR system. Expert Review of Molecular Diagnostics, 2021, 21, 333-342.	3.1	6
407	Comparison of Aptima and hybrid captureâ€2 HPV tests and Pap test in the referral population in Japan. Journal of Medical Virology, 2021, 93, 5076-5083.	5.0	3
408	Split-type electrochemiluminescent gene assay platform based on gold nanocluster probe for human papillomavirus diagnosis. Biosensors and Bioelectronics, 2021, 178, 113044.	10.1	19
409	HPV-Negative Cervical Cancer: A Narrative Review. Diagnostics, 2021, 11, 952.	2.6	18
410	Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework. Journal of Clinical Microbiology, 2021, 59, .	3.9	6
411	Infections à papillomavirus : actualités sur le dépistage et la vaccination. Option/Bio, 2021, 32, 21-23.	0.0	1
412	Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework. Journal of Virological Methods, 2021, 292, 114118.	2.1	2
413	Updated evidence-based recommendations for cervical cancer screening in France. European Journal of Cancer Prevention, 2022, 31, 279-286.	1.3	14
414	Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting. Journal of Clinical Virology, 2021, 140, 104851.	3.1	1
415	Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa. PLoS ONE, 2021, 16, e0255124.	2.5	7
416	Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework. Journal of Virological Methods, 2021, 294, 114161.	2.1	2
417	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	6.0	116
418	A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada. Preventive Medicine Reports, 2021, 23, 101448.	1.8	5
420	Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer. International Journal of Women's Health, 2021, Volume 13, 841-859.	2.6	31
421	Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecologic Oncology, 2021, 162, 575-583.	1.4	27
422	Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program. American Journal of Clinical Pathology, 2022, 157, 390-398.	0.7	4
423	Comparison of Alinity m HPV and cobas HPV assays on cervical specimens in diverse storage media. Tumour Virus Research, 2021, 12, 200224.	3.8	1
424	New techniques. , 2010, , 891-902.		2

#	Article	IF	CITATIONS
425	Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework. Journal of Clinical Virology, 2020, 128, 104336.	3.1	11
426	Intrinsic fluorescence for cervical precancer detection using polarized light based in-house fabricated portable device. Journal of Biomedical Optics, 2018, 23, 1.	2.6	13
427	Human Papillomaviruses. , 0, , 1783-1802.		1
428	Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus. Journal of Clinical Microbiology, 2020, 59, .	3.9	7
429	Pathological discrepancy between colposcopic directed cervical biopsy and conisation results: A five years experience of a single center in Turkey. Pakistan Journal of Medical Sciences, 2019, 35, 1627-1630.	0.6	1
430	Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. PLoS ONE, 2014, 9, e86835.	2.5	58
431	HPV prevalence and HPV-related dysplasia in elderly women. PLoS ONE, 2018, 13, e0189300.	2.5	40
432	HPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile. Salud Publica De Mexico, 2013, 55, 162-169.	0.4	20
433	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. Oncotarget, 2017, 8, 72438-72446.	1.8	8
434	Evidence based appropriate triage strategies for implementing high risk HPV as primary technology in cervical cancer screening. Minerva Ginecologica, 2020, 72, 96-105.	0.8	4
435	Cervical Cancer and Genital Infections: Assessment of Performance and Validation in Human Papillomavirus Genotyping Assays in Iran, its Neighbouring Countries and Persian Gulf Area. Iranian Journal of Pathology, 2017, 12, 35-44.	0.5	14
436	Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix. Asian Pacific Journal of Cancer Prevention, 2019, 20, 377-382.	1.2	7
437	Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery, 2012, 11, Doc09.	0.8	54
438	Genotipos de virus papiloma humano (VPH) en pacientes con cáncer cervico-uterino en un hospital público y una clÃnica privada de Santiago, Chile. Revista Chilena De Infectologia, 2010, 27, .	0.1	4
439	Clinical Validation of the BD Onclarity? HPV Assay Using a Non-Inferiority Test. , 0, s3, .		8
440	Evaluation of HPV Molecular Tests in Primary Screening for Cervical Cancer in Brazil. Open Journal of Obstetrics and Gynecology, 2014, 04, 470-478.	0.2	7
441	Cervical cancer screening in Switzerland: time to rethink the guidelines. Swiss Medical Weekly, 2015, 145, w14112.	1.6	11
442	Clinical Utility of Adjunctive High-Risk Human Papillomavirus DNA Testing in Women With Papanicolaou Test Findings of Atypical Glandular Cells. Archives of Pathology and Laboratory Medicine, 2010, 134, 103-108.	2.5	35

# 443	ARTICLE Repurposing the Hybrid Capture 2 (HC2) screening test for whole-genome sequencing of human papillomaviruses. Archives of Virology, 2021, 166, 3421-3425.	IF 2.1	CITATIONS 2
445	Genital Human Papillomavirus Infections. , 2010, , 186-202.		0
446	Laboratory Diagnosis of HPV and its Clinical Use. , 2011, , 539-546.		0
447	Building Sustainable Capacity for Disease Diagnosis in Sub-Saharan Africa: Case Studies of Cooperation in Diagnostic Pathology. , 0, , .		1
449	HPV TESTING AND CERVICAL CANCER EXAMINATION : PROSPECTS IN CERVICAL CANCER EXAMINATION. Juntendo Medical Journal, 2013, 59, 236-240.	0.1	0
451	15 Optimale afname van cellen van de baarmoederhals voor cervixscreening. , 2013, , 199-206.		0
452	Hybrid Capture 2 Assay Based Evaluation of High-Risk HPV Status in Healthy Women of North-East India. Asian Pacific Journal of Cancer Prevention, 2014, 15, 861-865.	1.2	10
453	THE ROLE OF CYTOLOGICAL AND VIROLOGICAL STUDIES IN SECONDARY PREVENTION OF CERVICAL CANCER. Russian Journal of Infection and Immunity, 2014, 4, 148.	0.7	0
454	Molecular Methods for Identification of Cultured Microorganisms. , 0, , 12.3.1.1-12.3.13.6.		0
455	Cervical Cancer Screening at a Crossroads: Learnings from the Past Driving Change for the Future. , 0, , .		0
456	Human Papillomaviruses (HPVs). , 2017, , 21-43.		0
457	Investigation and Typing of Human Papillomavirus in Cervical Swab Samples. Journal of Gynecological Research and Obstetrics, 2017, 3, 070-074.	0.3	0
458	Cervical Cancer Screening in Low-Resource Settings. , 2019, , 167-185.		1
459	Zervixkarzinom-Screening. Springer Reference Medizin, 2020, , 1-6.	0.0	0
460	DETECTION OF HUMAN PAPILLOMA VIRUS BY «SELF SAMPLING»: A NEW MODEL OF CERVICAL CANCER SCREENING. Modern Medical Technologies, 2020, 47, .	0.2	0
461	Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study. Lancet Regional Health - Europe, The, 2021, 11, 100235.	5.6	36
462	New HPV16 viral biomarkers to understand the progression of cervical lesions towards cancer. Indian Journal of Medical Research, 2014, 139, 487-9.	1.0	1
463	Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall. International Journal of Clinical and Experimental Pathology, 2015, 8, 16089-96.	0.5	1

#	Article	IF	CITATIONS
464	Title is missing!. Journal of Virus Eradication, 2017, 3, 1-10.	0.5	4
465	Cervical Cancer and Genital Infections: Assessment of Performance and Validation in Human Papillomavirus Genotyping Assays in Iran, its Neighbouring Countries and Persian Gulf Area. Iranian Journal of Pathology, 2017, 12, 35-44.	0.5	11
466	Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework. Journal of Clinical Pathology, 2023, 76, 172-176.	2.0	0
468	Abbott Alinity m HR-HPV, a novel human papillomavirus assay for primary cervical cancer screening, is adapted to HPV guidelines. Journal of Clinical Virology Plus, 2021, 1, 100055.	1.0	0
469	Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway. MDM Policy and Practice, 2022, 7, 238146832110710.	0.9	0
470	Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework. Journal of Molecular Diagnostics, 2022, 24, 365-373.	2.8	2
471	Role of Dual-Staining p16/Ki-67 in the Management of Patients under 30 Years with ASC-US/L-SIL. Diagnostics, 2022, 12, 403.	2.6	1
472	Clinical Performance of DNA and RNA Based HPV Tests for Test of Cure (TOC) Post Treatment for Cervical Intraepithelial Neoplasia (CIN) - a Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
473	Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data. Microbiology Spectrum, 2022, 10, e0157021.	3.0	2
474	HPV testing of self-samples: Influence of collection and sample handling procedures on clinical accuracy to detect cervical precancer. Lancet Regional Health - Europe, The, 2022, 14, 100332.	5.6	12
475	Human Papillomavirus E6/E7 oncogene transcripts as biomarkers for the early detection of cervical cancer. Journal of Medical Virology, 2022, 94, 3368-3375.	5.0	9
476	Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. International Journal of Gynecological Cancer, 2022, 32, 716-723.	2.5	3
477	A comprehensive HPV-STI NGS assay for detection of 29 HPV types and 14 non-HPV sexually transmitted infections. Infectious Agents and Cancer, 2022, 17, 9.	2.6	3
478	Reply to: Comments on "Metaâ€analysis of agreement/concordance statistics in studies comparing self― vs clinicianâ€collected samples for HPV testing in cervical cancer screening― International Journal of Cancer, 2022, 151, 484-487.	5.1	0
479	Comments on: "Metaâ€analysis of agreement/concordance statistics in studies comparing self―vs clinician ollected samples for HPV testing in cervical cancer screening― International Journal of Cancer, 2022, 151, 481-483.	5.1	2
480	Preliminary establishment and validation of a loop-mediated isothermal amplification assay for convenient screening of 13 types of high-risk human papillomaviruses in cervical secretions. Journal of Virological Methods, 2022, 303, 114501.	2.1	3
481	The Seasonal and Demographic Trends of National HPV Screening Program in City of NiÄŸde: The Effects of COVID 19 Pandemic. Turkish Journal of Public Health, 2022, 20, 152-163.	0.4	3
482	Merkel Cell Polyoma Virus and Cutaneous Human Papillomavirus Types in Skin Cancers: Optimal Detection Assays, Pathogenic Mechanisms, and Therapeutic Vaccination. Pathogens, 2022, 11, 479.	2.8	4

#	Article	IF	CITATIONS
483	Clinical performance of DNA and RNA based HPV tests for Test of Cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study Journal of Clinical Virology, 2022, 150-151, 105165.	3.1	0
484	Ancillary Techniques for the Diagnosis of Glandular Lesions of the Female Genital Tract. Monographs in Clinical Cytology, 2011, 20, 101-106.	0.1	0
485	Clinical Validation of the Fully Automated NeuMoDx HPV Assay for Cervical Cancer Screening. Viruses, 2022, 14, 893.	3.3	1
486	Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples. Journal of Translational Medicine, 2022, 20, 231.	4.4	8
487	Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ, The, 0, , e068776.	6.0	13
488	False Negative Results in Cervical Cancer Screening—Risks, Reasons and Implications for Clinical Practice and Public Health. Diagnostics, 2022, 12, 1508.	2.6	6
489	Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncology, The, 2022, 23, 950-960.	10.7	28
490	Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping. PLoS ONE, 2022, 17, e0267836.	2.5	3
491	Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment. Diagnostics, 2022, 12, 1748.	2.6	5
492	Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme. Medicine (United States), 2022, 101, e29530.	1.0	3
493	Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population. PLoS ONE, 2022, 17, e0272721.	2.5	3
494	Concordance between the BD Onclarity and Roche cobas assays for detection of HPV DNA in a Chinese population Journal of Medical Virology, 0, , .	5.0	0
495	Clinical Performance of the RealTi <i>m</i> e High Risk HPV Assay on Self-Collected Vaginal Samples within the VALHUDES Framework. Microbiology Spectrum, 2022, 10, .	3.0	8
496	IPVS Policy Statement on HPV Nucleic Acid Testing Guidance for Those Utilising/Considering HPV as Primary Precancer Screening: Quality Assurance and Quality Control Issues. SSRN Electronic Journal, 0, , .	0.4	0
497	Can HPV Selfy be considered as a clinically validated HPV test for use in cervical cancer screening?. Journal of Translational Medicine, 2022, 20, .	4.4	0
499	Untold story of human cervical cancers: HPV-negative cervical cancer. BMB Reports, 2022, 55, 429-438.	2.4	10
500	Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 2177-2184.	2.5	11
501	The possibilities of opportunistic cervical screening in the assisted reproductive technology clinic. Opuholi Zenskoj Reproduktivnoj Sistemy, 2022, 18, 102-108.	0.4	0

#	Article	IF	CITATIONS
502	HPV test as a primary screening test in the prevention of cervical carcinoma in the Republic of Croatia. , 2022, 96, 323-332.		0
503	Review of HPV testing for primary cervical cancer screening. , 2022, 96, 279-301.		0
504	Prevalence of cervical high-risk human papillomavirus and cytological abnormalities in elderly Turkish women. Marmara Medical Journal, 0, , .	0.8	0
505	The Implementation of a Primary HPV Self-Testing Cervical Screening Program in Malaysia through Program ROSE—Lessons Learnt and Moving Forward. Current Oncology, 2022, 29, 7379-7387.	2.2	7
507	International experience of laboratory methods in the cervical cancer screening. Russian Journal of Oncology, 2022, 26, 177-187.	0.1	0
508	Widening the offer of human papillomavirus selfâ€sampling to all women eligible for cervical screening: Make haste slowly. International Journal of Cancer, 2023, 153, 8-19.	5.1	5
509	IPVS POLICY STATEMENT ON HPV NUCLEIC ACID TESTING guidance for those utilising/considering HPV as primary precancer screening: Quality Assurance and Quality Control issues Journal of Clinical Virology, 2022, , 105349.	3.1	6
510	The Optimal Management of Neisseria gonorrhoeae Infections. Microorganisms, 2022, 10, 2388.	3.6	0
511	Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENTâ€⊋ framework. Journal of Medical Virology, 2023, 95, .	5.0	0
512	Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk. International Journal of Molecular Sciences, 2023, 24, 1320.	4.1	0
513	Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women. International Journal of Gynecological Cancer, 2023, 33, 669-675.	2.5	1
514	Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study. Archives of Gynecology and Obstetrics, 2023, 308, 207-218.	1.7	1
515	Influence of resuspension volume on dry sampling devices taken for human papillomavirus testing: implications for self-sampling. BioTechniques, 2023, 74, 77-84.	1.8	2
516	Artificial Intelligence, Bioinformatics, and Pathology. Advances in Molecular Pathology, 2023, , .	0.4	0
517	CIN2 + detection in high-risk HPV patients with no or minor cervical cytologic abnormalities: a clinical approach validated by machine learning. Archives of Gynecology and Obstetrics, 2023, 307, 881-890.	1.7	1
518	POSIBILITIES OF THE APPLICATION OF DIFFERENT TEST-SYSTEMS FOR MOLECULAR-GENETIC DETECTION OF HPV DNA IN THE PREVENTIVE PROGRAMS AGAINST CEVICAL CANCER. Problemy Zdorovʹâ I Ã'kologii, 2010, , 19-21.	0.1	0
519	The Significance of Cytology, Biopsy, and HPV Testing. , 2023, , 67-105.		0
520	Quality assurance in human papillomavirus testing for primary cervical screening. International Journal of Gynecological Cancer, 2023, 33, 802-811.	2.5	9

#	Article	IF	CITATIONS
521	Updates on cervical cancer prevention. International Journal of Gynecological Cancer, 2023, 33, 394-402.	2.5	10
522	Impact of HPV molecular testing with partial genotyping as a feasibility study in cervical cancer community screening program in South India. Journal of Medical Virology, 2023, 95, .	5.0	0
523	HPV Cotesting of Unsatisfactory Papanicolaou Tests: Implications for Follow-up Intervals. American Journal of Clinical Pathology, 2023, 160, 137-143.	0.7	2
524	Evaluation of Seegene Anyplex II Performance for Detection of Human Papillomavirus Genotypes in Formalin-Fixed, Paraffin-Embedded Cervical Cancer Specimens. Archives of Pathology and Laboratory Medicine, 2024, 148, 353-358.	2.5	Ο
525	Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex HPV28 Assays for High-Risk HPV Detection and Genotyping in Mocked Self-Samples. Microbiology Spectrum, 2023, 11, .	3.0	1
526	Human Papilloma Virus DNA Detection in Clinical Samples Using Fluorogenic Probes Based on Oligonucleotide Gated Nanoporous Anodic Alumina Films. Advanced Healthcare Materials, 2023, 12, .	7.6	2
527	Clinical Performance of Cobas 6800 for the Detection of High-Risk Human Papillomavirus in Urine Samples. Vaccines, 2023, 11, 1071.	4.4	0
528	HPV self-sampling among cervical cancer screening users in Spain: A randomized clinical trial of on-site training to increase the acceptability. Preventive Medicine, 2023, 173, 107571.	3.4	2
529	No woman left behind: achieving cervical cancer elimination among women living with HIV. Lancet HIV,the, 2023, 10, e412-e420.	4.7	4
530	Comparison of the Clinical Accuracy of Xpert HPV Assay on Vaginal Self-Samples and Cervical Clinician-Taken Samples within the VALHUDES Framework. Journal of Molecular Diagnostics, 2023, 25, 702-708.	2.8	2
531	The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review. Pathogens, 2023, 12, 908.	2.8	1
532	Evaluation of the implementation of screening programs for early detection of breast and cervical cancer in the Gomel region. Problemy ZdorovE1A¢ I A kologii, 2023, 20, 88-97.	0.1	0
533	HPV-Testverfahren. , 2023, , 99-108.		0
534	Cervical Cancer Screening Recommendations: Now and for the Future. Healthcare (Switzerland), 2023, 11, 2273.	2.0	4
535	Re: â€~2020 list of human papillomavirus assays suitable for primary cervical cancer screening' by Arbyn etÂal Clinical Microbiology and Infection, 2023, 29, 1606-1607.	6.0	1
536	Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing. PLOS Global Public Health, 2023, 3, e0001982.	1.6	1
537	Can REALQUALITY RQ-HPV screen be considered as a clinically validated HPV test for use in cervical cancer screening?. Clinical Microbiology and Infection, 2023, 29, 1608-1609.	6.0	0
538	HPV Testing and its Role in Cervical Cancer Screening. Clinical Obstetrics and Gynecology, 2023, 66, 448-469.	1.1	0

Ę

#	Article	IF	CITATIONS
539	Accuracy of Human Papillomavirus (HPV) Testing on Urine and Vaginal Self-Samples Compared to Clinician-Collected Cervical Sample in Women Referred to Colposcopy. Viruses, 2023, 15, 1889.	3.3	3
540	Intra―and interlaboratory reproducibility of the RIATOL qPCR HPV genotyping assay. Journal of Medical Virology, 2023, 95, .	5.0	1
541	Performance of the <scp>HPV E6</scp> / <scp>E7 mRNA</scp> Aptima <scp>HPV</scp> assay combined with partial genotyping compared with the <scp>HPV DNA</scp> Cobas 4800 <scp>HPV</scp> test for use in primary screening: Results from the <scp>CERVIVA HPV</scp> primary screening study in Ireland. International Journal of Cancer, 2024, 154, 53-64.	5.1	0
542	Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening?. European Journal of Cancer Prevention, 0, , .	1.3	0
543	Clinical performance of the novel fullâ€genotyping <scp>OncoPredict HPV</scp> Quantitative Typing assay using the <scp>VALGENT</scp> framework. International Journal of Cancer, 2024, 154, 538-547.	5.1	0
544	A Glimmer of Hope for Patients with a T3 Transformation Zone: miRNAs Are Potential Biomarkers for Cervical Dysplasia. Diagnostics, 2023, 13, 3599.	2.6	0
545	Comparative Performance of Anyplex II HPV28 and Cobas 4800 Human Papillomavirus (HPV) Assays for High-Risk HPV Detection in Self-collected Anal Samples. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
546	Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study. Lancet Oncology, The, 2023, 24, 1349-1358.	10.7	0
547	HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial. BMC Cancer, 2023, 23, .	2.6	0
548	Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening. Journal of Clinical Epidemiology, 2024, 166, 111227.	5.0	0
549	Evaluation of self-sampling-based cervical cancer screening strategy using HPV Selfy CE-IVD test coupled with home-collection kit: a clinical study in Italy. European Journal of Medical Research, 2023, 28, .	2.2	0
550	Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening. Journal of Clinical Virology, 2024, 170, 105638.	3.1	0
551	Comparison of high-risk HPV detection by the AmpFire® HPV Screening 16/18/HR technique (Atila) Tj ETQq0 () 0 rgBT /O	verlock 10 Tf
552	Methods for meta-analysis and meta-regression of binomial data: concepts and tutorial with Stata command metapreg. Archives of Public Health, 2024, 82, .	2.4	0
553	Validation of the clinical performance and reproducibility of the NeuMoDx HPV assay self-sample workflow. Journal of Clinical Virology, 2024, 171, 105649.	3.1	0
554	Prevalence and significance of HPV DNA detection below the clinical threshold of the commercial kit Alinity m HRâ€HPV assay (Abbott). Journal of Medical Virology, 2024, 96, .	5.0	0
555	Analytical evaluation of the automated genotyping system (GenPlex) compared to a traditional realâ€ŧime PCR assay for the detection of highâ€ŧisk human papillomaviruses. Journal of Medical Virology, 2024, 96, .	5.0	0
556	DNA methylation as a triage tool for cervical cancer screening – A meeting report. Preventive Medicine Reports 2024 41, 102678	1.8	0

#	Article	IF	CITATIONS
557	2023 global inventory of commercial molecular tests for human papillomaviruses (HPV). Journal of Clinical Virology, 2024, 172, 105671.	3.1	0